Radionuclide Therapy of Leukemias and Multiple Myeloma-Reference-Cited by-同舟云学术

Radionuclide Therapy of Leukemias and Multiple Myeloma

Published:2022 Issue: Volume: Page:1-52
ISSN:
Container-title:Nuclear Oncology
language:
Short-container-title:

Author:

Sollini Martina,Bartoli Francesco,Galimberti Sara,Boni Roberto,Erba Paola A.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-319-26067-9_48-2

Reference295 articles.

1. Richman CM, DeNardo SJ, O’Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005;11:5920–7.

2. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer. 2002;94:1363–72.

3. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896–902.

4. Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;00:1–14.

5. Advani AS, Mcdonough S, Coutre S, et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014;165:504–9.